Product Program year 2025 Source: CMS Open Payments

Qfitlia

Drug Hematology

NDC 58468-0347-1

Open in the dashboard

General payments

$652,353

742 payments

Research payments

$0

0 payments

Through program year 2025, $652,353 in general payments and $0 in research payments were reported against Qfitlia (Hematology).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

1 row
Year Kind Amount Payments
2025 General $652,353 742

Breakdown

Who paid General payments · program year 2025
  1. Genzyme Corporation $652,353 742 payments
Top recipients General payments · program year 2025
  1. Guy Young Pediatric Hematology-Oncology · Bozeman, MT $115,660 18% · 52 payments
  2. Tammuella Chrisentery-Singleton Pediatric Hematology-Oncology · New Orleans, LA $49,706 8% · 24 payments
  3. Maissaa Janbain Hematology & Oncology · New Orleans, LA $46,153 7% · 18 payments
  4. Vinod Balasa Pediatric Hematology-Oncology · Madera, CA $45,951 7% · 23 payments
  5. Vanessa Salinas-Luna Pediatric Hematology-Oncology · Orange, CA $44,089 7% · 33 payments

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2025
  1. Pediatric Hematology-Oncology Pediatrics $453,572 70% · 76 practitioners
  2. Hematology & Oncology Internal Medicine $75,900 12% · 67 practitioners
  3. Pediatrics $49,756 8% · 14 practitioners
  4. Hematology Internal Medicine $22,248 3% · 12 practitioners
  5. Nurse Practitioner, Family Nurse Practitioner $21,557 3% · 41 practitioners

The top 5 of 29 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2025
  1. California $262,645 40% · 24 recipients
  2. Louisiana $98,839 15% · 13 recipients
  3. Florida $79,501 12% · 36 recipients
  4. Texas $43,554 7% · 44 recipients
  5. Nevada $30,724 5% · 5 recipients

The top 5 of 37 states; each share is of general payments naming this product in 2025 where a state was reported.

The top 25 states, free in the app

742 general

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record